News
The companies aiming to beat cancer serve up the highlights in the June quarter
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion by 2030 and expand growth at a CAGR of 9.1%…
News
Challenging the pace of change in healthcare: Prescient Therapeutics
“The fact of the matter is there are people walking around now who shouldn’t be alive, but they are because of our trials, which is…
News
Prescient (ASX: PTX) makes ‘solid progress on all fronts’ in June quarter
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022 quarter, which saw ‘solid progress on all fronts’. The ASX-listed…
News
ASX Quarterlies: From fintech to biotech, these small caps have delivered strong performances for shareholders
It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last…
News
Prescient Therapeutics (ASX:PTX) advances clinical programs in June quarter
Prescient Therapeutics (PTX) advanced multiple clinical programs for its targeted and cell therapy drugs over the June quarter.
News
Prescient first in class cancer drug PTX-100 granted Orphan Drug status by the US FDA
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market exclusivity and other commercial benefits in blood cancer PTCL. Clinical…
News
Prescient Therapeutics’ PTX-100 for peripheral T-cell lymphoma treatment granted US orphan drug status
The designation brings considerable benefits including guaranteed market exclusivity for seven years and a waiver of Prescription Drug User Fee Act fees for orphan drugs,…
News
Prescient Therapeutics (ASX: PTX) Presentation – Switzer Small & Micro Cap Investor Day – July 2022
Prescient Therapeutics (ASX: PTX) Managing Director and CEO Steven Yatomi-Clarke presents at the Switzer Small & Micro Cap Investor Day July 2022 where he discusses…
News
Prescient Therapeutics granted key US patent for OmniCAR portfolio of therapies
Prescient Therapeutics Ltd (ASX:PTX) has been granted a US patent for its flagship OmniCAR portfolio entitled ‘SpyCatcher and SpyTag: Universal Immune Receptor for T Cells’ that…
News
FIVE at FIVE AU: Iron ore cops a belting and energy prices could stay high until 2025
All the major banks have now lifted interest rates in line with the Reserve Bank of Australia’s cash rate hike of 0.5% yesterday, however that…